Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 CAR-T cell therapy - Juno Therapeutics

Next Previous
Drug Profile

Anti-CD19 CAR-T cell therapy - Juno Therapeutics

Alternative Names: 1928z-41BBL CAR T cells; Armored CAR modified T Cells; CD19-directed 4-1BBL armored CAR - Juno Therapeutics; EGFRt/19-28z/4-1BBL CAR T cells

Latest Information Update: 31 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 31 Mar 2021 Interim efficacy and adverse events data from a phase I trial in haematological malignancies released by Pharmaceuticals (Actinium Pharmaceuticals SEC filing, March 2021)
  • 28 Apr 2020 No recent reports of development identified for phase-I development in Haematological-malignancies(Recurrent, Refractory metastatic disease) in USA (Parenteral, Infusion)
  • 16 Jun 2019 Interim efficacy and adverse events data from a phase I trial in Haematological-malignancies presented at the 24th Congress of the European Haematology Association (EHA-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top